HSBC cut shares of Smith & Nephew (LON:SN) to a hold rating in a research report released on Tuesday, October 16th. The firm currently has GBX 1,500 ($19.60) target price on the stock, up from their prior target price of GBX 1,400 ($18.29).
Other research analysts have also issued reports about the company. Deutsche Bank reissued a sell rating on shares of Smith & Nephew in a report on Friday, July 20th. UBS Group lowered Smith & Nephew to a neutral rating and cut their price objective for the company from GBX 1,470 ($19.21) to GBX 1,340 ($17.51) in a report on Wednesday, August 8th. Finally, Numis Securities increased their price objective on Smith & Nephew from GBX 1,350 ($17.64) to GBX 1,480 ($19.34) and gave the company an add rating in a report on Thursday, July 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the stock. Smith & Nephew presently has an average rating of Hold and a consensus price target of GBX 1,425.50 ($18.63).
Shares of LON SN remained flat at $GBX 1,395 ($18.23) during mid-day trading on Tuesday. The company had a trading volume of 1,927,173 shares, compared to its average volume of 3,250,000. Smith & Nephew has a 1 year low of GBX 1,173 ($15.33) and a 1 year high of GBX 1,442 ($18.84).
About Smith & Nephew
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Read More: Understanding Relative Strength Index
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.